Generic biotech medicines could save Marylanders nearly $1.4 billion

Published



The use of generic biotech medicines could save Marylanders a reported $1.388 billion over a 10-year period and an estimated $71 billion across the U.S., according to a report issued by St. Louis-based Express Scripts, one of the largest pharmacy benefit management companies in North America and a major prescription plan provider in Maryland.

Key to this cost savings are both the enactment of the Access To Life-Saving Medicine Act of 2007, sponsored by Sen. Hillary Clinton, D-N.Y., and others, and the release of federal guidelines by the Food and Drug Administration for generic biotech medicines.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.